Immunome's varegacestat shows promising efficacy in desmoid tumors, with phase 3 topline data expected by 2025-end. Read why ...

Some oncologists and researchers have raised concerns about delays in the completion of confirmatory trials, but FDA now has new tools to push them ahead.

Merck MRK announced mixed second-quarter results last month. The company beat estimates for earnings while meeting the same ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A Newsweek report reveals America's Most Responsible Companies for 2025, with a New Jersey-based company earning the top spot ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Since its inception, Merck Foundation has provided 63 scholarships to Nigerian doctors, enabling them to specialise in 42 ...

Health Secretary Robert F. Kennedy Jr. is vowing to "fix" the federal program for compensating Americans injured by vaccines, ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...